Perspective Therapeutics, Inc.

AI-generated fair value estimate for this company.

Method: Risk-adjusted NPV (rNPV) on lead pipeline asset plus net cash: VMT-a-NET (212Pb-radiolabeled alpha therapy for SSTR2+ neuroendocrine tumors, Phase 1/2a advancing to Phase 3) modeled with $750M un-risked peak sales (benchmarked to Novartis's Lutathera, a beta-emitter NET radioligand doing ~$500-600M/yr with a stated $1B target, with a premium for VMT-a-NET's differentiated alpha-particle mechanism and 43% interim response rate) and a 25% peak unlevered FCF margin (reflecting costly alpha-isotope manufacturing/supply chain); 30% probability of success (industry-average Phase 2-to-approval rate for oncology); revenue/FCF ramp from 10% of peak at launch (assumed 2029) to 100% of peak by year 6 post-launch, then 2% perpetual terminal growth; 12% discount rate; risk-adjusted lead-asset NPV of ~$331M, plus ~$50M of risk-adjusted optionality value for the secondary pipeline (VMT01 melanoma, PSV359 FAP+ tumors, PSV594, all Phase 1/2a-or-earlier); plus $237M net cash (cash, equivalents and short-term investments as of June 30, 2026, de minimis debt); total ~$618M divided by 114.15M shares outstanding.

Reasoning: CATX is a clinical-stage radiopharmaceutical biotech with negligible product revenue (TTM revenue ~$0.4M), so a conventional DCF on current financials is not meaningful; an rNPV grounded in a real, named comparable (Lutathera) for peak sales, a standard industry probability-of-success rate, and the company's actual disclosed cash balance is the appropriate framework, and the well-funded balance sheet (runway into late 2027) materially de-risks near-term financing risk.